Detalhe da pesquisa
1.
PRL2 phosphatase enhances oncogenic FLT3 signaling via dephosphorylation of the E3 ubiquitin ligase CBL at tyrosine 371.
Blood;
141(3): 244-259, 2023 01 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36206490
2.
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
Cancer;
130(2): 287-299, 2024 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37801052
3.
Structural racism is a mediator of disparities in acute myeloid leukemia outcomes.
Blood;
139(14): 2212-2226, 2022 04 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35061876
4.
Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy.
Blood;
140(25): 2663-2671, 2022 12 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35930750
5.
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Blood;
140(17): 1845-1857, 2022 10 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35917453
6.
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
Ann Hematol;
103(1): 105-116, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38036712
7.
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw;
22(1): 43-69, 2024 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38394770
8.
Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11.
Eur J Haematol;
112(6): 964-974, 2024 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38388794
9.
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
Am J Hematol;
99(4): 606-614, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38342997
10.
TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity.
Cancer;
129(2): 175-180, 2023 01 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36397669
11.
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw;
21(5): 503-513, 2023 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37156478
12.
Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype.
Br J Haematol;
197(6): 736-744, 2022 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35304738
13.
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Blood;
135(7): 463-471, 2020 02 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31841594
14.
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
Am J Hematol;
97(3): 322-328, 2022 03 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34981560
15.
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).
Cancer;
127(23): 4421-4431, 2021 12 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34424530
16.
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
Cancer;
127(8): 1246-1259, 2021 04 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33270904
17.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
N Engl J Med;
378(25): 2386-2398, 2018 Jun 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29860938
18.
Identification and targeting of novel CDK9 complexes in acute myeloid leukemia.
Blood;
133(11): 1171-1185, 2019 03 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30587525
19.
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Blood;
133(7): 676-687, 2019 02 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30510081
20.
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
J Natl Compr Canc Netw;
19(1): 16-27, 2021 01 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33406488